4142:TPE
Adimmune Corp
NT$16.35
arrow_downward
-1.51%(-0.25) 1દિ
6 નવે, 01:30:04 PM GMT+8 · TWD
search
બધા પ્રતીકો
| પ્રતીક | ભાવ | ફેરફાર | ફેરફાર %માં |
|---|
insights_auto4142 માટે મુખ્ય જાણકારીઓ જનરેટ કરી રહ્યાં છીએ...
ખોલો
NT$16.05
ઉચ્ચ
NT$16.50
ઓછો
NT$15.65
માર્કેટ કૅપિટલાઇઝેશન
7.02 અબજ
સરેરાશ વૉલ્યૂમ
10.76 લાખ
વૉલ્યૂમ
21.59 લાખ
52-અઠવાડિયામાં ઉચ્ચ
NT$22.50
52-અઠવાડિયામાં ન્યૂનતમ
NT$15.65
EPS
-NT$0.34
બાકી રહેલા શેર
23.53 કરોડ
કર્મચારીઓની સંખ્યા
564
ખોલો
NT$16.05
ઉચ્ચ
NT$16.50
ઓછો
NT$15.65
માર્કેટ કૅપિટલાઇઝેશન
7.02 અબજ
સરેરાશ વૉલ્યૂમ
10.76 લાખ
વૉલ્યૂમ
21.59 લાખ
52-અઠવાડિયામાં ઉચ્ચ
NT$22.50
52-અઠવાડિયામાં ન્યૂનતમ
NT$15.65
EPS
-NT$0.34
બાકી રહેલા શેર
23.53 કરોડ
કર્મચારીઓની સંખ્યા
564
ન્યૂઝ સ્ટોરી
વેબ સૉર્સ અને ન્યૂઝ પાર્ટનર તરફથી
Finviz
·
1 કલાક પહેલાં
PSQ Holdings Shrinks Losses And Cash Burn, But Slowing Growth, A Steep Q4 Target And NYSE Listing Risk Define The Setup
Investing.com
·
10 મિનિટ પહેલાં
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.26%
Barron's
·
2 કલાક પહેલાં
Stock Momentum Has Reversed. One Chart Spells It Out.
Seeking Alpha
·
54 મિનિટ પહેલાં
Top 20 S&P 500 Ranked By PEG Ratio After Massive Tech Route (NYSEARCA:SPY)
પ્રોફાઇલ
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp વિશે